Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
Atsuko ChiharaAtsushi TanakaTakeshi MorimotoMio SakumaMichio ShimabukuroTakashi NomiyamaOsamu ArasakiShinichiro UedaKoichi NodePublished in: Cardiovascular diabetology (2019)
These findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy. Trial registration ClinicalTrials.gov number NCT02330406. https://clinicaltrials.gov/ct2/show/NCT02330406; registered January 5, 2015.
Keyphrases
- low density lipoprotein
- study protocol
- cardiovascular disease
- phase iii
- clinical trial
- coronary artery disease
- phase ii
- computed tomography
- randomized controlled trial
- type diabetes
- mesenchymal stem cells
- magnetic resonance imaging
- bone marrow
- stem cells
- open label
- dual energy
- positron emission tomography
- replacement therapy
- double blind